Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
about
Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patientsCD133: to be or not to be, is this the real question?The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor CellsStem cell technology in breast cancer: current status and potential applicationsEvaluation and consequences of heterogeneity in the circulating tumor cell compartmentAldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumorsMetastasis of circulating tumor cells: favorable soil or suitable biomechanics, or both?Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer researchCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionDissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the HaystackThe Challenges of Detecting Circulating Tumor Cells in SarcomaStem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancerEMT, CTCs and CSCs in tumor relapse and drug-resistanceMesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cellsMesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties.HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells.Analysis of circulating tumor cells in breast cancer.Beta-elemene blocks epithelial-mesenchymal transition in human breast cancer cell line MCF-7 through Smad3-mediated down-regulation of nuclear transcription factors.Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasisCirculating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients.The role of adipose-derived stem cells in breast cancer progression and metastasis.Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy.Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer CellsTherapeutic Implications of Cellular Heterogeneity and Plasticity in Breast CancerCancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.CD151 promotes α3β1 integrin-dependent organization of carcinoma cell junctions and restrains collective cell invasionClinical challenges in the molecular characterization of circulating tumour cells in breast cancer.Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment.High cell-surface density of HER2 deforms cell membranesSilencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells.Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells.
P2860
Q21284707-13FD9049-E4F5-474C-92EE-8325B0F35103Q24615405-CFB11E5E-3CD7-4FE3-81D5-F98C46C6F31DQ26741223-7C25E640-FC7C-4E11-8D3C-9F054DE68B54Q26746223-F89CCBFF-C0A9-470A-A21C-03F66583E99FQ26765357-BA10442E-8CA1-435D-A251-F8E55A4A7A22Q26786476-1E83FFC5-C768-4D82-BD19-7118FE5B501AQ26796595-92151B54-3F05-4FA1-B350-0C0C084DBAFBQ27024191-0705EFB3-8BDF-472F-BD49-A69CB22094D3Q28066285-AFEF3335-B4A2-459E-91FF-19B032E866DDQ28067549-53B3A8D5-E95E-4914-B729-67ED35C5BCCCQ28078659-AEEDD487-7DC1-4F8A-A0A0-F778159BBCF6Q28079205-13D1ECF2-9539-435A-BA02-651B9B3B4EFFQ28082935-22F7D2AC-302B-4DA2-BC64-DE75E9CFBDA9Q29048401-B7FBAF3E-4D07-4004-800F-0F6D88285AB8Q31158116-F7023AAD-3D4B-44BB-B23F-2356DEA16D38Q33618285-2AA23A8A-A336-4C5D-8B76-83D37BF04AE5Q33674656-30E91534-65E4-4276-A015-EA58A2B269CAQ33734993-0249657B-B3BB-442B-9FB7-3F1CDAD3AF26Q33737278-7CB98E49-A882-47B6-95E6-8510E097247DQ33829270-7A7BB67A-59F4-41AC-A7B2-6611523C942EQ33955293-D7FE5745-B3B8-4E74-8D28-3F15C1E60946Q34156275-F7FDA909-0D45-493F-BD42-1CE44CB85152Q34629931-4D6B392E-B2F8-4437-B684-F0BEAA37A210Q34797751-FB5CFC5E-2D3F-401F-BE1B-71C5078ED20DQ35000278-FFE59D2F-B0B7-4F54-9E40-00FF8CB45410Q35000298-13CBE65B-DFD0-4122-9C5D-9FEF2948752DQ35592378-C588F43C-E2C2-42A8-A8B2-C2BEFFB56F15Q35640863-F3CE954A-3677-4D7A-88FA-1A76A8FEF07CQ35710589-A317377F-9D31-43CE-AB5D-89823270BC28Q36030226-DAE518C2-26F2-47DA-A124-13AEF49AC892Q36544839-E21AA9F3-E165-4EFE-9F96-46B3105B0500Q36618624-4541B2A4-BD92-47CC-A3F6-B6B69A524F28Q36747333-B6EE5FC4-B300-44FB-90F6-5464E4AB9970Q36838910-B3D309F6-AAB6-487E-89E5-A2A02B5C715CQ36959162-D25A8554-54D3-4316-8931-2D1034B9EDADQ37015722-9066E32D-B8B0-48AF-904F-5D8EFA522F86Q37115286-3F697083-9BA3-436C-A892-06A65A68735CQ37257182-5888566A-BECF-4B2E-823B-F7DE3C2DF8E6Q37323067-28FFBB1E-0C01-4EC9-9CF0-03192346D3E4Q37420601-E320B765-22AF-4134-B689-E3F381BAEDD0
P2860
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Epithelial-mesenchymal transit ...... tive metastatic breast cancer.
@ast
Epithelial-mesenchymal transit ...... tive metastatic breast cancer.
@en
type
label
Epithelial-mesenchymal transit ...... tive metastatic breast cancer.
@ast
Epithelial-mesenchymal transit ...... tive metastatic breast cancer.
@en
prefLabel
Epithelial-mesenchymal transit ...... tive metastatic breast cancer.
@ast
Epithelial-mesenchymal transit ...... tive metastatic breast cancer.
@en
P2093
P2860
P50
P1476
Epithelial-mesenchymal transit ...... itive metastatic breast cancer
@en
P2093
Bang-Ning Lee
Charla A Parker
James M Reuben
Massimo Cristofanilli
Michal Mego
Naoto T Ueno
Ricardo H Alvarez
Sabino De Placido
P2860
P304
P356
10.1158/1535-7163.MCT-12-0460
P577
2012-09-12T00:00:00Z